Algan Group Health Services continues to work with the vision of creating innovative products that will contribute to human life in our country and in the world. Saylan Utku Bozdağ, General Manager of Algan Group Health Services, shared the origin story and goals of the company story with our readers.
What is origin story of Algan Group Health Services?
Under the leadership of me, Algan Group Health Services was founded in 2017 by expert scientists in biotechnology, medicine and biogengineering with the aim of improving and developing the products and treatment methods available in the sector, using high biotechnology. Algan Group Health Services, whose investments and researches in the field of health are based on pre-incorporation, continuously follow the medical device technologies and biotechnology around the world, but focus on the better, produce high-tech products, fast-acting and low incidence of side effects, and continue its R&D. As you know, new diseases and epidemics appear in the world every day. The rapid change experienced especially after Covid-19 necessitates the development of new surgical operation systems along with new treatment methods in all areas of health.
What are your product types?
In parallel with our goal, we produced our first product, blood-stopper Algan Hemostatic Agent, and we have completed all the permits of our FOAM, POWDER, LIQUID, SPONGE products manufactured in GMP standards and put them into use. In addition, we continue to work on our biotechnological products at the R&D stage without slowing down. By following the developing technology of the changing world and developing new technologies, we focused on being one of the leading biotechnology companies in our country and in the world.
Could you inform us about your goals?
As Algan, our goal is to be one step ahead of the disease in treatment, to provide easy access to treatment for patients, to facilitate surgical operations of healthcare professionals, to maximize the survival probability of people by reducing the risk, and to compete with every company in the market by focusing on all available treatment areas. As Algan Group Health Services, which was established with 100% Turkish capital, we focused on being the leading biotechnology company in our country and in the world by following the developing technology of the changing world and developing new technologies. We aim to reduce the foreign dependency of our country in Technological Medical devices and biotechnological products with the unrivaled products we have developed as a result of the R&D studies, and to contribute to the country’s economy by presenting the technologies and products that are not produced in our country but brought from abroad and developed in foreign markets.
What sets you apart from other companies?
The blood stopper market in the world is approaching 8 billion USD. This market is shared by global companies. These companies continue to progress in their production with a single product suitable for surgical operations or the use of security forces. We, on the other hand, are the first and only biotechnology company that produces focused on all treatment areas. By using this superiority, we will compete with all global companies that dominate the market. We aim to become the largest biotechnology company in the world by developing more effective and more reliable products produced with superior technologies than the products of these companies. In parallel with this goal, we produced our first product, blood-stopper Algan Hemostatic Agent. And we have completed all the permissions of our FOAM, POWDER, LIQUID, SPONGE products manufactured in GMP standards and put them into use. In addition, we continue to work on our biotechnological products at the R&D stage without slowing down. In addition, we focused on being one of the leading biotechnology companies in our country and in the world by following the developing technology of the changing world and developing new technologies.
